8-K: Evofem Biosciences and Windtree Therapeutics Amend License and Supply Agreement for PHEXXI

Evofem Biosciences and Windtree Therapeutics have amended their License and Supply Agreement to clarify terms related to manufacturing and supply of PHEXXI.

Summary

• Evofem Biosciences, Inc. and Windtree Therapeutics, Inc. amended their License and Supply Agreement on March 28, 2025.
• The amendment clarifies definitions and terms, including the effective date of the agreement, the binding forecast period, and the purchase price.
• It also addresses potential supply chain disruptions and delivery dates.
• Windtree will be the sole manufacturer and supplier of PHEXXI, excluding US-produced product requirements from Evofem's customers.
• Evofem can maintain alternate suppliers in case of delays or disruptions and can conduct manufacturing trial runs with new potential suppliers.
• The binding forecast period is four months prior to the scheduled manufacturing date, and Evofem can reduce orders by up to 20% within this period without penalties.
• The purchase price is set at $15 per twelve-count box for the first three years or until Windtree recovers its tech transfer costs, after which the parties will negotiate a reduced price.
• Evofem has the right to initiate a recall or corrective action relating to the Products and shall provide prompt written notice thereof to Supplier.
• Supplier agrees to reimburse, indemnify, and hold Buyer harmless from all costs and damages arising from any such Recall or general corrective action, including its costs for retrieving and replacing the Products if such Recall is a result of the breach of any of Suppliers warranties or requirements of the Quality Agreement with respect to the manufacture of the Products as set forth herein.

Sentiment

Score: 7

Explanation: The document reflects a neutral to slightly positive sentiment, as it clarifies and strengthens a key supply agreement. The provisions for flexibility and potential cost reductions are also viewed favorably.

Positives

• The amendment clarifies key terms of the agreement, potentially reducing future disputes.
• Evofem retains flexibility to use alternate suppliers in case of disruptions, ensuring supply continuity.
• The agreement includes provisions for price reductions if Evofem finds cheaper suppliers.
• The agreement includes provisions for Evofem to be reimbursed, indemnified, and held harmless from all costs and damages arising from any such Recall or general corrective action, including its costs for retrieving and replacing the Products if such Recall is a result of the breach of any of Suppliers warranties or requirements of the Quality Agreement with respect to the manufacture of the Products as set forth herein.

Negatives

• The agreement includes a clause where Evofem can terminate the agreement if there are two or more instances of Nonconforming Product in any twelve (12) months period during the Term.
• Windtree's liability is capped at the greater of the amounts paid by Buyer for product(s) in the twelve months preceding the event giving rise to the claim or one million dollars ($1,000,000).

Risks

• Supply chain disruptions could allow Evofem to cancel purchase orders and source products from other suppliers, potentially impacting Windtree's revenue.
• If there are two or more instances of Nonconforming Product in any twelve (12) months period during the Term, then Buyer may terminate this Agreement upon notice to Supplier and Buyer shall not have any further liability to Supplier pursuant to this Agreement, any Purchase Order or any forecast.
• Windtree's liability is capped at the greater of the amounts paid by Buyer for product(s) in the twelve months preceding the event giving rise to the claim or one million dollars ($1,000,000).

Future Outlook

The amendment aims to solidify the manufacturing and supply relationship between Evofem and Windtree for PHEXXI, with provisions for flexibility and potential cost reductions.

Management Comments

• No direct management quotes are provided in the document.

Industry Context

This agreement is typical in the pharmaceutical industry, where companies often outsource manufacturing to specialized firms. The amendment reflects ongoing adjustments to ensure a stable and cost-effective supply chain.

Comparison to Industry Standards

• The agreement's exclusivity clause is standard in pharmaceutical manufacturing agreements, ensuring dedicated production capacity.
• The pricing structure, with an initial fixed price followed by potential reductions, is common to reflect economies of scale and cost efficiencies.
• The liability caps and indemnification clauses are also typical risk-sharing mechanisms in such agreements.
• Comparable companies that engage in similar manufacturing and supply agreements include Teva Pharmaceutical Industries and Mylan (now Viatris), which often outsource production of generic drugs to contract manufacturers.

Stakeholder Impact

• Shareholders: The amendment provides clarity and stability to the supply chain, which could positively impact investor confidence.
• Employees: The agreement ensures continued production of PHEXXI, supporting job security.
• Customers: A stable supply chain ensures consistent availability of PHEXXI.
• Suppliers: The agreement defines the relationship between Evofem and Windtree, impacting their respective suppliers.

Next Steps

• Windtree will continue manufacturing PHEXXI according to the amended agreement.
• Evofem will monitor Windtree's performance and explore potential cost reduction opportunities.
• The parties will negotiate a reduced price after Windtree recovers its tech transfer costs.

Key Dates

Keywords

Evofem Biosciences, Windtree Therapeutics, PHEXXI, License Agreement, Supply Agreement, Amendment, Manufacturing, Supply Chain, Pharmaceuticals